BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
2.487
-0.043 (-1.70%)
At close: Sep 18, 2026, 4:00 PM EDT
2.540
+0.053 (2.13%)
After-hours: Sep 18, 2026, 7:30 PM EDT
BioLineRx Revenue
BioLineRx had revenue of $294.00K in the quarter ending June 30, 2026, a decrease of -3.29%. This brings the company's revenue in the last twelve months to $1.39M, down -91.93% year-over-year. In the year 2025, BioLineRx had annual revenue of $1.18M, down -95.92%.
Revenue (ttm)
$1.39M
Revenue Growth
-91.93%
P/S Ratio
8.08
Revenue / Employee
$58,000
Employees
24
Market Cap
11.24M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.18M | -27.76M | -95.92% |
| Dec 31, 2024 | 28.94M | 24.14M | 502.92% |
| Dec 31, 2023 | 4.80M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 5.34M |
| Vistagen Therapeutics | 2.50M |
| Daré Bioscience | 1.37M |
| CytoMed Therapeutics | 669.28K |
| Azitra | 7.50K |
BLRX News
- 9 days ago - BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) - PRNewsWire
- 19 days ago - BioLineRx Releases Q2 2026 Financial Results - AlphaStreet
- 19 days ago - BioLineRx Earnings Call Transcript: Q2 2026 - Transcripts
- 19 days ago - BioLineRx Earnings release: Q2 2026 - Filings
- 19 days ago - BioLineRx reports Q2 EPS 0c vs 0c last year - TheFly
- 19 days ago - BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 22 days ago - BioLineRx prices 1.35M ADSs at $2.78 in registered direct offering - TheFly
- 22 days ago - BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - PRNewsWire